To retrospectively identify target recall rates for screening mammography on the basis of how sensitivity shifts with recall rate.
C
onsiderable variation in recall rates exists between different mammographers, practices, and countries (1) (2) (3) (4) . Whereas some variation may be because of differences among the populations being screened and the ability of the radiologist, much is almost certainly because of variation in radiologist preference with regard to the importance of finding every cancer (reflected in their sensitivity) and tolerance of false-positive findings at examinations (reflected in their specificity and positive predictive value [PPV] ). The recall rate in a facility is defined as the percentage of screening studies for which further work-up is recommended. Recall rates in screening programs and facilities have been reported to range from less than 1% to about 15% for screening mammography (1, 5) . Across screening programs, recall rate has been shown to be positively correlated with sensitivity and negatively correlated with PPV (1, 5) . Thus, use of a lower recall rate places a greater emphasis on maintaining a high PPV, while use of a higher recall rate places greater value on achieving high sensitivity.
Different groups have recommended different target recall rates. European guidelines recommend a target recall rate of 5%, with an acceptable rate of less than 7% for first screenings and a target recall rate of 3% (acceptable rate Ͻ5%) for subsequent screenings (6, 7) . The American College of Radiology and the U.S. Agency for Health Care Policy and Research both recommend an overall recall rate of less than 10% (8, 9) . However, to our knowledge, these targets have not been evaluated relative to their effect on sensitivity and PPV on the basis of data that reflect current mammographic screening examinations within clinical practice in the United States.
Thus, the goal of our study was to retrospectively identify target recall rates for screening mammography on the basis of how sensitivity shifts with recall rate.
Materials and Methods

Study Data
The study group included all screening mammograms from 1996 to 2001 from six sites of the Breast Cancer Surveillance Consortium (BCSC) from which data from individual facilities were available. The BCSC is a consortium of mammographic facilities funded by the National Institutes of Health for the purpose of evaluating the performance of mammography in the community setting (10) and represents a diverse U.S. population (11) . Seven community-based mammographic registries located in Vermont, New Hampshire, North Carolina, Colorado, New Mexico, California, and the state of Washington have created mammographic databases that link with population-based cancer databases. Each registry and the Statistical Coordinating Center (SCC) of the BCSC has received a federal certificate of confidentiality and approval from each institution's review board for the protection of human subjects to collect and send data (12) to the SCC and to conduct research with these data. Three of seven sites were granted a waiver of informed consent. At three of the other sites, women had the option to exclude their data from research. At one site, the patient's signature was required to allow inclusion of data for research. This study was Health Insurance Portability and Accountability Act compliant.
For our study, data from one site were not included because that site did not collect data at the facility where mammography was performed.
All data related to the screening mammographic examination were collected at the facility at the time of mammography. At mammography, patients completed a breast health survey, which included date of birth, history and date of previous mammography, and reported presence of breast signs and symptoms (lump, nipple discharge, or others, not including breast pain).
The interpreting radiologist recorded the indication for the examination, additional imaging studies performed, and date of previous mammography. In addition, breast density and mammographic assessment were recorded by using the recommended categories of the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) (13) . Breast density was categorized as extremely dense, heterogeneously dense, scattered fibroglandular densities, or almost entirely fat. Mammographic assessment was performed with the following categories: 0, needs additional imaging evaluation; 1, negative finding; 2, benign finding; 3, probably benign finding; 4, suspicious abnormality; and 5, highly suggestive of malignancy.
The registries collected breast cancer information from regional Surveillance, Epidemiology, and End Results programs, state cancer registries, and pathology databases. Cancers were categorized as either invasive disease or ductal carcinoma in situ. (Lobular carcinoma in situ was considered benign for this analysis.) 
Mammographic Assessment
All mammographic studies were assessed by radiologists with BI-RADS assessments. The follow-up period for all screening mammography was 12 months or the time to the next screening examination, if that occurred between 9 and 12 months later. For our sensitivity calculations, a screening mammographic examination was considered to yield a positive finding if the assessment was needs further evaluation, suspicious abnormality, suspicious for malignancy (BI-RADS categories 0, 4, and 5, respectively), or probably benign (category 3) when accompanied by a recommendation for immediate imaging follow-up. A screening mammographic examination was considered to yield a negative finding if the assessment was normal, benign (BI-RADS categories 1 and 2, respectively), or probably benign (BI-RADS category 3) and did not have a recommendation for immediate follow-up.
Reference Standard
A mammogram with a positive finding yielded a true-positive finding (TP) if cancer was diagnosed and a false-positive finding (FP) if cancer was not diagnosed in the follow-up period. A mammogram with a negative finding yielded a true-negative finding (TN) if no breast cancer was diagnosed and a false-negative finding (FN) if cancer was diagnosed in the follow-up period.
Sensitivity was defined as the proportion of cancers that were detected, calculated as TP/(TP ϩ FN). Specificity was defined as the proportion of individuals without cancer correctly classified as having a negative finding at mammography, calculated as TN/(TN ϩ FP). Recall rate was defined as the proportion of individuals recalled for additional work-up, calculated as (TP ϩ FP)/(TP ϩ FP ϩ TN ϩ FN). Cancer incidence per 1000 mammograms was calculated as 1000
Statistical Analysis
Sensitivity increases with recall rate, but not necessarily linearly. By using a four-step procedure, a nondecreasing, monotonic, piecewise linear fit to the data was constructed for sensitivity as a function of recall rate on the basis of facility-level data that were weighted by the number of cancers. First, isotonic regression analysis (14) was used to model sensitivity as a constant for various ranges of the recall rate. Isotonic regression provides the least-squares fit to the raw data among the class of all monotonic functions. Second, reduced monotonic regression (15) (␣* ϭ .50) was used to identify the recall rate groups by combining isotonic regression level sets with similar sensitivity measures. Third, the reduced monotonic regression model was adjusted for site, mean age of women, and percentage of long-interval mammographic examinations (defined for subsequent mammograms as the percentage of mammograms at the facility whose previous mammograms were more than 27 months earlier). Breast density and percentage of women with a personal history of breast biopsy were not included in these adjustments because of incomplete and/or inconsistent reporting across the facilities. Fourth, a concave, monotone, piecewise linear fit (called "concave fit" henceforth) was obtained by joining the mean recall rates for the adjusted sensitivities of the recall rate groups. A piecewise linear segment was used to span multiple groups, if a nonincreasing slope with increasing recall (the concavity requirement) was needed. Separate fits were obtained for first and subsequent mammograms.
We provide a brief explanation of the four-step modeling procedure as follows. Because of random variation, virtually no regression relationships are perfectly ordered. In our case, sensitivity does not perfectly increase with increasing recall rate. The recall rate groups provide regions of the domain (recall rate in our case) where the response (sensitivity in our case) is found to be fairly constant. Because we do not believe that sensitivity is intrinsically flat, with jump points at certain recall rates, we use the recall rate groups to construct the concave fit by using linear interpolation of points.
The slopes for the piecewise linear segments were interpreted as number of additional work-ups per additional cancer detected (AW/ACD 
Results
Overall, 171 104 first and 1 872 687 subsequent mammograms obtained at 172 facilities from six BCSC sites were included. Performance measures for the study population were stratified by using demographic characteristics (Table 2) . For subsequent mammograms, the mean recall rate was 8.1%, with a sensitivity of 78.2% and a PPV of 5.0%. The overall cancer rate was 5.15 cancers per 1000 mammograms (9650/1 872 687). For first mammograms, the recall rate was 13.2%, with a sensitivity of 85.9% and a PPV of 3.5%. The overall cancer rate was 5.32 cancers per 1000 mammograms (910/171 104). Sensitivity and PPV generally increased with increasing patient age for both first and subsequent mammograms. While the recall rate predominantly decreased with increasing patient age for subsequent mammograms, it increased from the younger than 40 years age group to the 50 -59 years age group before decreasing for first mammograms.
Subsequent Mammograms
The association between sensitivity and recall rate for subsequent screening mammography was modeled by using a concave fit (Fig 1) , which was constructed by using the seven recall rate groups obtained from the reduced monotonic regression fit (Table 1) . For example, in the third recall rate group, 1019 women from 30 facilities had breast cancer at the follow-up period, with a mean recall rate of 4.3% (range, 3.2%-5.2%) and a sensitivity of 69.1%.
As the recall rate increases, so does the AW/ACD value (Fig 2) . For example, increasing recall rate from 1.1% to 2.5% would require an estimated 29 additional work-ups to find one additional cancer, compared with 51 for increasing recall rates from 2.5% to 4.3%. The two groups with the lowest mean recall rates (1.1% and 2.5%) represent only six facilities and less than 4% of mammographic examinations performed. Thus, the two groups represent recall rates that most mammographers find to be unacceptably low. The shift from group 3 to group 4 is associated with an estimated AW/ACD of 80; 84.1% of screening mammograms were evaluated at facilities at or beyond recall rate group 4. Group 4, with recall rates between 5.3% and 9.2%, was the largest, representing 75 facilities that performed 47.8% of all subsequent mammograms. Recall rate groups 5 and 6 (range, 9.3%-13.6%) were associated with a single shift of AW/ACD of 132, due to the concavity requirement; 29.8% of mammograms were screened at these recall rates. An additional 6.5% of mammograms were screened at recall rates higher than 14%, associated with a very high AW/ACD of 304.
Recall rate group 4, with a mean recall rate of 6.7%, represents the best choice for mammographers who wish to maximize their sensitivity while keeping the estimated AW/ACD less than 100. Group 4 facilities accounted for 47.8% of mammograms evaluated, with 15.9% and 36.3% of women being screened at facilities with lower and higher recall rates, respectively (Table 1) . Estimated performance measures for recall rates ranging from 3% to 12% were obtained from the concave fit (Table 3) ; this information might be useful to mammographers contemplating shifts in their individual recall rates.
First Mammograms
The association between sensitivity and recall rate for first screening mammography was modeled with a concave fit, which had a single shift in AW/ACD estimates (Fig 3) , on the basis of four recall rate groups (Table 4) . Recall rate group 2 had the greatest number of mammograms, at 53.7%, and a recall rate range of 6.1%-13.2%, with an average of 10%. Recall rate group 3, with recall rates ranging from 13.3% to 23.1%, reflects the practices where 40.4% of mammograms were evaluated. Recall rate groups 1 and 4 represent exceptionally low (2.4%-6.0%) and high (23.2%-27.9%) practice patterns, seen in a total of 10 practices (5.9% of patients).
These four recall rate groups give rise to a single shift in AW/ACD. Below 10%, the estimated value was 35, compared with 172 for higher recall rates. Thus, a target recall of 10% is the best choice for mammographers who wish to maximize their sensitivity while keeping the estimated AW/ACD below either 50 or 100 (Fig 4) . Group 2 facilities, whose recall rates include the target rate of 10%, accounted for 53.7% of cancers detected, with 3.4% and 42.9% of women being screened at facilities with lower and higher recall rates, respectively (Table 4) .
Discussion
For a given mammographer, sensitivity clearly increases with recall rate, because recalling additional women from a given cohort could not decrease the true-positive rate. Indeed, if all women were recalled, very few cancers would be missed. Consequently, establishing a target recall rate should not be based on maximizing sensitivity alone. Judgment is needed to settle on a recall rate at which the additional yield of cancers detected is not worth the additional number of recalls. Such a decision is difficult, because it represents a trade-off between the benefit of finding additional cancers and the increased number of procedures for noncancers and the associated anxiety and monetary cost that women experience as they undergo further work-ups (16) (17) (18) . It seems reasonable that values of AW/ACD should be below the prevailing cancer rate. We believe that the best choices for recall rate targets are those that represent the mean recall rates for one of the recall rate groups established in the Results section. By using the metric of AW/ACD, a detriment (additional workup) to benefit measure of increasing or decreasing recall rate, individual mammographers may be able to gauge the effect that changing their recall rate by 1% would have on performance.
While individual mammographers and informed patients may have different ideas regarding the optimal tradeoff, we suggest using an AW/ACD of, at most, 100. This benchmark level seems to be a good choice. In our study, a level larger than 132 would lead to a target recall rate of 12.3%, which is higher than that recommended by American College of Radiology guidelines (8, 9) . A level below 80 would result in a target recall rate of 4.3%. The latter rate is close to European guidelines (6,7), which call for rates below 5%. However, less than 15% of U.S. patients underwent mammography at facilities with rates at or below that rate. The resulting target recall rates are 10.0% for first mammograms and 6.7% for subsequent mammograms. Notably, the recall rate groups with the largest percentages of mammograms evaluated include these target rates, with a small percentage below these rates and a sizable percentage above-42.9% of first and 36.3% of subsequent mammograms. European guidelines of less than 5% for subsequent screenings correspond to a lower tolerance for AW/ACD (6, 7) . Interpreted according to our concave fit, their recommendations would suggest use of a maximum AW/ACD between 51 and 80, which would lead to a recall rate group with a 4.3% mean recall rate and 69% sensitivity. Their guideline for less than 7% recalls after first screenings would place them in the lower end of the 6.1%-13.2% recall rate group given in Table 4, which corresponds to an 83.3% sensitivity. Yankaskas et al (19) showed that these differences do exist when comparing international screening recall rates. In a meta-analysis of 24 mammographic screening programs, Elmore et al (1) concluded that "the percentage of mammograms judged to be abnormal in North American programs was 2-4 percentage points higher than it was in programs from other countries without evident benefit in the yield of cancers detected per 1000 women screened, although an increase was noted in DCIS [ductal carcinoma in situ] detection." This may be exaggerated because they included BI-RADS category 3 as a recall, which is not done internationally or in this study.
Yankaskas et al (5) concluded that facilities with recall rates between 4.9% and 5.5% achieved the best trade-off of sensitivity and PPV. Their range of recall rates was obtained by performing reduced monotonic regressions on the relationships of sensitivity and PPV with recall rate and by identifying the range in which both sensitivity and PPV were maintained at high levels. Our study is nearly 10 times larger than theirs and, to our knowledge, is the largest study to date to examine this issue in the United States. We believe that it improves on that study by splitting mammograms into first and subsequent screenings and by using the concave fit approach, with its accompanying AW/ACD concept. Their target rate is between the reasonable targets of 4.3% and 6.7% presented by us.
There is some concern about the establishment of recall rate guidelines in mammography. Gur et al (20) examined the correlation between recall and cancer detection rates in a group of 10 radiologists from a single academic institution. Noting an increase in the presumed linear relationship, where the recall rates ranged from 7.7% to 17.2%, they concluded that "the performance level of a radiologist in the screening environment is a complex, multifactorial issue that cannot and should not be simplified. Reducing recall rates by "decree" (through the enforcement of recommended practice guidelines) may result in a corresponding reduction in the detection rates." Their study results, however, focused on detection rates, which lack the additional information on missed cancers that is available with sensitivity. They also modeled the relationship between the recall and detection rates as linear. Consequently, their evidence cannot suggest that any level of recall rate is too high. Inspection of their data suggests that beyond about a 12% recall rate, little or no gain in the detection rate occurred. In a recent commentary, Hardesty et al (21) suggested usage of three nonlinear models to determine the sensitivity-recall rate relationship, including a concave fit, which they erroneously called convex. We used a concave fit in our analysis, which we believe makes sense clinically because discrimination between cancer and noncancer as the recall rate increases becomes increasingly difficult.
In a re-review of missed cancers from a Dutch breast screening program that has the lowest recall rate worldwide, Otten et al (22) examined the effect of increasing the recall rate. In their article, 15 mammographers rereviewed 495 screening mammograms with negative findings for subsequent screenings, which included 245 missed cancers, from which they extrapolated their outcome measures to 500 000 subsequent screenings by using an equivalent concept to AW/ACD. For recall rates between 4% and 7%, their AW/ ACD values were 30%-70% higher than ours. For recall rates between 8% and 10%, their AW/ACD values were within 14% of ours. It is unclear whether the higher values they obtained are because of differences in mammographic evaluation between the United States and the Netherlands, different screening intervals, or the relatively few cancers on which they based their estimates.
Our study had limitations. The relationship between recall rate and sensitivity was assessed by using seven community-based registries in the United States. Extension of these results to other U.S. states and to other regions of the world cannot be assumed from statistical principles but must rather be based on subjective judgment. Because the women included in the BCSC are largely representative of women undergoing screening mammography within the United States, however, we believe it is likely that most radiologists' patients will be similar to those within the BCSC (11). Sensitivity differences were found between the states. We believe that this is most likely because of differences in completeness in identifying cancers between the various state registries. This site difference was adjusted for in obtaining our models, with North Carolina as the referent group because it provided the largest number of mammograms to this study. Thus, the actual sensitivities will differ by state. However, the locations where the AW/ACD rates shifted were modeled as being the same for all sites. As further data are accrued, additional covariates affecting the sensitivities or, perhaps, the location of AW/ACD rate shifts may be found. However, to our knowledge, this study represents the largest collective evidence on the recall rate-sensitivity relationship published to date and incorporates the data from the secondlargest study (5) .
The data and analysis presented demonstrate a wide variation in recall rate-sensitivity pairs in this convenience sample of U.S. radiologists. This variation likely represents both different preferences and different abilities among radiologists. Clustering of the facilities' results, together with analysis of the gains from additional work-up for these radiologists, strongly suggests ranges of targeted performance. We recommend operating at a target recall rate of approximately 6.7% for subsequent mammograms and 10.0% for first mammograms, because these rates keep the estimated number of AW/ACD lower than 100.
